Cibinqo®, Dupixent®, Adtralza®, RINVOQ®
Abrocitinib (Cibinqo®), dupilumab (Dupixent®), tralokinumab (Adtralza®) and upadacitinib (RINVOQ®) for the treatment of atopic dermatitis are reimbursed on the High Tech Arrangement. There are two Managed Access Protocols (MAPs) in place for these high tech medicines for the treatment of atopic dermatitis:
- For adults and adolescents 12 years and older: HSE-Managed Access Protocol for high tech medicines for the treatment of moderate-to-severe atopic dermatitis.
- For children 6 years to 11 years old: HSE-Managed Access Protocol for dupilumab (Dupixent®) for the treatment of severe atopic dermatitis in children 6 years to 11 years old.
These MAPs outline the criteria that must be satisfied in order for a patient to be recommended for reimbursement of abrocitinib, dupilumab, tralokinumab or upadacitinib for the treatment of atopic dermatitis through the relevant protocol under the High Tech Arrangement.
Applications for reimbursement approval of these medicines for the treatment of atopic dermatitis under the High Tech Arrangement will only be considered from consultant dermatologists registered with the Irish Medical Council, practising in the healthcare system in the Republic of Ireland, and who have agreed to the terms of the relevant MAP and been approved by the HSE. The approved consultant must submit an application for individual reimbursement approval for each patient.
A copy of each MAP can be found in the Related Files section below.
For further information, please contact mmp@hse.ie.